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T cells requires antigen translocation into
the cytosol for proteasomal degradation.
Burgdorf and colleagues demonstrate
that such translocation is mediated by
Sec61, a protein from the ER, which is
translocated toward antigen-containing
endosomes after stimulation of the
dendritic cell with pro-inflammatory
factors.
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The molecular mechanisms regulating antigen trans-
location into the cytosol for cross-presentation are
under controversial debate, mainly because direct
data is lacking. Here, we have provided direct evi-
dence that the activity of the endoplasmic reticulum
(ER) translocon protein Sec61 is essential for endo-
some-to-cytosol translocation. We generated a
Sec61-specific intrabody, a crucial tool that trapped
Sec61 in the ER and prevented its recruitment into
endosomes without influencing Sec61 activity and
antigen presentation in the ER. Expression of this
ER intrabody inhibited antigen translocation and
cross-presentation, demonstrating that endosomal
Sec61 indeed mediates antigen transport across
endosomal membranes. Moreover, we showed that
the recruitment of Sec61 toward endosomes, and
hence antigen translocation and cross-presentation,
is dependent on dendritic cell activation by Toll-like
receptor (TLR) ligands. These data shed light on a
long-lasting question regarding antigen cross-pre-
sentation and point out a role of the ER-associated
degradation machinery in compartments distinct
from the ER.
INTRODUCTION
Adaptive immune responses are induced when dendritic cells
(DCs) encounter antigens in the peripheral tissue. Upon antigen
recognition, DCs become activated and migrate toward the
draining lymph node, where they present the internalized and
processed antigens on major histocompatibility (MHC) proteins
to T cells. Antigens presented onMHC Imolecules can be recog-
nized by antigen-specific cytotoxic T cells, whereas T helper
cells recognize antigens presented on MHC II.850 Immunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc.In addition to the MHC I-restricted presentation of endoge-
nous antigens, a separate process termed cross-presentation
enables extracellular antigens to be presented onto MHC I
molecules as well. This presentation pathway is a specialized
function of DCs essential, e.g., for the induction of cytotoxic
T cell responses against viruses that do not infect DCs or against
tumors from non-hematopoietic origin (Joffre et al., 2012).
Despite intensive investigations, the molecular mechanisms
regulating cross-presentation are not fully understood. In gen-
eral, cross-presentation can occur via two major pathways: the
vacuolar pathway and the endosome-to-cytosol pathway (Joffre
et al., 2012), which is considered to be the most relevant one
(Rock and Shen, 2005). In the vacuolar pathway, internalized an-
tigens are degraded within endosomal compartments by lyso-
somal proteases and loaded onto recycling MHC I molecules
there (Shen et al., 2004). In the endosome-to-cytosol pathway,
antigens need to be translocated from the endosome into the
cytosol, where they are degraded by the cytosolic proteasome
(Ackerman et al., 2003). Antigen-derived peptides are then re-
translocated into endosomal compartments or into the ERwhere
loading takes place (Ackerman et al., 2003; Burgdorf et al., 2008;
Guermonprez et al., 2003; Houde et al., 2003).
A critical step in the endosome-to-cytosol pathway is the
export of internalized antigens out of endosomes into the
cytosol. Because the addition of Exotoxin A, which inhibits
the ER-associated degradation (ERAD) machinery, has been
shown to impair cross-presentation, several members of this
protein complex have been proposed to be involved in such
intracellular antigen translocation, including Sec61 and Derlin-1
(Ackerman et al., 2006; Amigorena and Savina, 2010; Giodini
and Cresswell, 2008). However, because direct experimental
data are still not available, the identification of this translocon re-
mains one of the most intriguing and controversially discussed
questions in antigen cross-presentation (Joffre et al., 2012; Kurts
and Wagner, 2011; Nair-Gupta and Blander, 2013; Segura and
Villadangos, 2011).
In this study, we provide compelling evidence that antigen
translocation into the cytosol is mediated by the translocon
Sec61, a member of the ERAD machinery that is recruited
Figure 1. Inhibition of the ERAD Machinery
Prevents Antigen Translocation and Cross-
Presentation
(A) BM-DCs were incubated with OVA in the
presence or absence of 10 mg/ml ExoA for 2 hr.
Then, BM-DCs were fixed and co-cultured with
OT I T cells. T cell activation was determined by
IL-2 ELISA.
(B) As in (A) using OT II T cells.
(C) BM-DCs were electroporated with OVA- or
GFP-encoding mRNA and incubated in the pres-
ence or absence of 10 mg/ml ExoA for 3 hr, fixed,
and co-cultured with OT I T cells.
(D) as in (A) using 10 nM SIINFEKL.
(E) BM-DCs were incubated with 5 mg/ml OVA or
10 nM SIINFEKL in the presence or absence of
10 mg/ml ExoA and stained with the 25.D1-16
antibody.
(F) BM-DCs were electroporated with OVA- or
GFP-encoding mRNA, incubated in the presence
or absence of ExoA and stained with the 25.D1-16
antibody.
(G) BM-DCs were treated with OVA in the pres-
ence of the proteasome inhibitor MG132 and in the
presence or absence of 10 mg/ml ExoA. Cytosolic
OVA was visualized after isolation of the cytosolic
fraction by Western blot. All graphs depict repre-
sentative results of at least three independent
experiments. Data are represented as mean ±
SEM. ExoA, ExotoxinA; MFI, mean fluorescence
intensity. See also Figure S1.toward antigen-containing endosomes after stimulation with en-
dotoxins. By the use of a unique Sec61-specific intrabody, we
could retain Sec61 in the ER and prevent its recruitment toward
antigen-containing endosomes, resulting in the prevention of
antigen translocation into the cytosol and cross-presentation.
RESULTS
Inhibition of the ER-Associated Degradation Machinery
Impairs Antigen Translocation for Cross-Presentation
Because it has been postulated that members of the ERAD ma-
chinery are responsible for antigen transport into the cytoplasm,
we first analyzed the effect of the two ERAD inhibitors Exotoxin A
(ExoA) (Ackerman et al., 2006) and Eeyarestatin I (EeyI) (Fiebiger
et al., 2004) on cross-presentation. To this end, we analyzed DCs
with OVA protein antigen in the presence or absence of both
inhibitors for activation of OVA-specific CD8+ T cells (OT I cells).
In accordance with previous observations (Ackerman et al.,
2006), cross-presentation in the presence of ExoA was clearly
diminished (Figure 1A), whereas MHC II-restricted presentationImmunity 42, 850–(Figure 1B), the MHC I-restricted pre-
sentation of endogenous antigens after
transfection of DCs with OVA-encoding
mRNA (Figure 1C), and T cell activation
by peptide-loaded DCs remained unal-
tered (Figure 1D), indicating that the effect
of ExoA was specifically on cross-pre-
sentation. Similar results were obtained
in the presence of EeyI (Figures S1A–S1D). The influence of both inhibitors on cross-presentation
was not due to altered amounts of internalized antigens,
because both ExoA and EeyI did not affect OVA uptake (Fig-
ure S1E). Staining with the 25.D1-16 antibody (Porgador et al.,
1997), which recognizes the OVA epitope SIINFEKL when pre-
sented on MHC I, revealed that the addition of ExoA decreased
the amount of peptide-loaded MHC I molecules after addition of
OVA (Figure 1E). In contrast, no influence of ExoA on 25.D1-16
staining was observed after endogenous expression of OVA
(Figure 1F), pointing out that ExoA might indeed influence the
molecular mechanisms of cross-presentation. Similar observa-
tions were made for EeyI (Figure S1F). To verify whether this in-
fluence was due to impaired antigen translocation in the cytosol,
we treated DCs with OVA in the presence of the proteasome in-
hibitor MG132, which allows the detection of translocated OVA
in the cytosol after isolation of the cytosolic fraction and subse-
quent analysis by immuno blot (Figures S1G and S1H) (Burgdorf
et al., 2008). By this means, we could demonstrate that both
ERAD inhibitors decreased the amount of OVA in the cytosolic
fraction (Figure 1G, Figure S1I), confirming a putative role of863, May 19, 2015 ª2015 Elsevier Inc. 851
Figure 2. Downregulation of Derlin-1 Does
Not Influence Cross-Presentation, MHC II-
Restricted Presentation, and T Cell Activa-
tion after Peptide Loading
(A) Downregulation of Derlin-1.
(B) BM-DCs were electroporated with siRNA. After
3 days, cells were incubated with OVA for 3 hr and
co-cultured with OT I T cells. T cell activation was
determined after 18 hr by ELISA.
(C) As in (B), using OT II T cells.
(D) As in (B) using 10 nMof SIINFEKL peptide. Data
are represented as mean ± SEM. All graphs depict
representative results of at least three independent
experiments. See also Figure S2.the ERAD machinery in antigen translocation into the cytosol for
cross-presentation.
Downregulation of Sec61 but Not Derlin-1 Prevents
Antigen Translocation into the Cytosol and Cross-
Presentation
To analyze which ERAD protein could be involved in intracellular
antigen translocation, we first downregulated Derlin-1, an ER
protein that plays a role in protein dislocation in the ER (Lilley
and Ploegh, 2004), by siRNA. We could demonstrate a downre-
gulation of Derlin-1 of 81.5% (siRNA A) or 69.8% (siRNA B)(Fig-
ure 2A). However, such downregulation did not influence antigen
presentation by the DCs (Figures 2B and 2C and 2D).
Next, we downregulated Sec61, a trimeric translocon complex
(consisting of an a, b, and g subunit) from the ER that regulates
protein transport across the ER membrane during protein trans-
lation and dislocation into the cytosol (Rapoport, 2007). Because
the main channel of the translocon is built by the a subunit of
Sec61 and two isoforms of this subunit are known, we identified
first which isoform is expressed by bone-marrow-derived DCs
(BM-DCs). RT-PCR experiments revealed the a1 isoform as
predominant with hardly any expression of the a2 isoform
(Figure 3A). Consistently, siRNAs against the a1 isoform downre-
gulated expression of Sec61, whereas downregulation of the
a2 subunit did not affect total Sec61a expression (Figure S2A
and S2B). Subsequently, we analyzed the effect of Sec61 down-
regulation on cross-presentation. At first sight, cross-presenta-
tion was markedly reduced using Sec61a1 siRNAs compared852 Immunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc.to control or Sec61a2 siRNAs (Fig-
ure S2C), pointing out a possible role of
Sec61 in cross-presentation. However,
MHC II-restricted presentation and T cell
activation after external DC loading with
the OVA epitope SIINFEKL were also
reduced (Figures S2D and S2E), suggest-
ing that the observed effects might not be
specific for cross-presentation.
To avoid the induction of such unspe-
cific effects, we loaded the DCs with
OVA only 1 day after siRNA transfection.
At this time point, a clear downregulation
of Sec61 could already be observed (Fig-
ure 3B, Figure S2B). Importantly, we fixed
the DCs immediately after OVA treatmentand before adding the T cells. By using this approach, we could
demonstrate that the reduction in Sec61 resulted in a reduced
cross-presentation (Figure 3C), whereas MHC II-restricted
presentation (Figure 3D), the presentation of endogenously ex-
pressed OVA in the ER (Figure 3E) and T cell activation after
external loading with SIINFEKL remained unaltered (Figure 3F),
excluding unspecific cytotoxic effects due to increased ER
stress.
Staining with the 25.D1-16 antibody demonstrated that
reduced cross-presentation was due to an impaired generation
of peptide-loaded MHC I molecules (Figure 3G), which was not
due to altered antigen internalization as Sec61 downregulation
did not affect OVA uptake (Figure 3H). To investigate whether
decreased cross-presentation was due to impaired antigen
translocation into the cytosol, we used three independent ap-
proaches. First, we analyzed at day one after transfection the
presence of internalized OVA in the cytosol by immunoblot as
described above. Transfection with siRNAs against Sec61a1
clearly impaired OVA translocation into the cytosol compared
to control or Sec61a2-specific siRNAs (Figure 3I), pointing out
that Sec61 indeed might play an important role in this process.
Second, we incubated siRNA-treated DCs with Cytochrome c
(Cyt c), which induces apoptosis upon translocation from the
endosomes into the cytoplasm (Lin et al., 2008). Downregulation
of Sec61a1 specifically reduced the induction of apoptosis
(Figure 3J), confirming the requirement of Sec61 for antigen
translocation. Third, we loaded DCs with CCF4, a cytosolic fluo-
rescence resonance energy transfer (FRET) substrate of the
b-lactamase. Internalization and translocation of externally
added b-lactamase into the cytosol results in cleavage of
CCF4 and can be quantified by flow cytometry as described
before (Cebrian et al., 2011). Downregulation of Sec61a1
reduced cleavage of CCF4 (Figure 3K), confirming again the
necessity of Sec61 for antigen translocation into the cytoplasm.
Next, we analyzed whether Sec61 also affected cross-presen-
tation of phagocytosed antigens and treated DCs with OVA-
coated beads. Similar to our observations for soluble ovalbumin,
downregulation of Sec61 impaired cross-presentation of OVA-
coated beads (Figure 3L), whereas MHC II-restricted presenta-
tion (Figure 3M) and overall uptake (Figure S3A) remained
unaffected. Additionally, translocation of bead-bound OVA
(Figure 3N), bead-bound Cyt c (Figure 3O) and bead-bound
b-lactamase (Figure 3P) were impaired after downregulation of
Sec61, demonstrating that the role of Sec61 in cross-presenta-
tion is not restricted to soluble antigens but also holds true for
particulate antigens.
To further define a specific role of Sec61 in antigen transloca-
tion, we downregulated Sec61g (Figure S3B), another essential
subunit of the Sec61 translocon, and analyzed the effects on
cross-presentation. In accordance to our experiments using
Sec61a1-specific oligos, downregulation of Sec61g also re-
sulted in reduced cross-presentation (Figure S3C), whereas
antigen uptake (Figure S3D), MHC II-restricted presentation
(Figure S3E), MHC I-restricted presentation of endogenous anti-
gens (Figure S3F), and T cell activation after peptide loading (Fig-
ure S3G) remained unaltered. Again, downregulation of Sec61g
clearly reduced the presence of OVA in the cytosolic fraction of
DCs (Figure S3H), the induction of apoptosis by external addition
of Cyt c (Figure S3I), and the cleavage of CCF4 after addition of
the b-lactamase (Figure S3J), showing the necessity of func-
tional Sec61 molecules for antigen translocation into the cytosol
and hence for cross-presentation.
In addition, we investigated the role of Hrd1, an ERAD-associ-
ated ubiquitin ligase present in the same protein complex as
Sec61 (Scha¨fer and Wolf, 2009), in cross-presentation. In a
recent study, it has been shown that Hrd1 is able to build a trans-
location pore even in the absence of Sec61 (Stein et al., 2014).
Downregulation of Hrd1 (Figure S3K) resulted in decreased
cross-presentation 2 days (Figure S3L), but not 1 day (Fig-
ure S3M), after siRNA treatment, whereas T cell activation after
external loading with SIINFEKL remained unaltered (Figure S3N).
Additionally, silencing of Hrd1 resulted in reduced OVA translo-
cation into the cytosol (Figure S3O). However, we also noticed
a clear reduction in MHC II-restricted presentation (Figure S3P).
Therefore, it remains unclear whether the observed effects on
cross-presentation are truly due to alterations in the cross-pre-
sentation machinery or rather to unspecific effects related to
the downregulation of Hrd1.
Sec61 Is Present in Antigen-Containing Endosomes
If Sec61 is indeed directly involved in antigen translocation from
endosomes into the cytosol, it needs to be present in antigen-
containing endosomes. To verify this hypothesis, we performed
immuno electron microscopy analysis of GFP-Sec61b in OVA-
treated DCs. Apart from a clear staining of the ER, we observed
the presence of Sec61 in intracellular vesicular structures
(Figure 4A). To verify whether these vesicles were indeedantigen-containing endosomes, we incubated the DCs with fluo-
rochrome-labeled OVA and performed correlative light and elec-
tron microscopy (CLEM) (Bos et al., 2014). As expected, we
monitored a clear Sec61 staining in the ER (Figure 4B). Addition-
ally, Sec61 was detected in the membrane of OVA-containing
endosomes (Figure 4C, Figure 4D), whereas no staining could
be detected in GFP-Sec61-negative cells within the same sam-
ple (Figure S4A) or the nucleus (Figure 4B).
To monitor Sec61 expression in endosomes in a quantitative
fashion, we transfected DCs with a GFP-Sec61 and treated
them with fluorochrome-labeled OVA. From these DCs, we iso-
lated a crude endosome fraction and analyzed it by flow cytom-
etry. In a previous study, we demonstrated that we can use this
technique to analyze the presence of specific proteins in individ-
ual, intact andmembrane-enclosed vesicles, whose identity was
unequivocally determined as endosomes by staining with the
early endosome markers Rab5 and the mannose receptor (Zeh-
ner et al., 2012). Figure 4E demonstrates that Sec61 was indeed
present in a substantial amount of antigen-containing endo-
somes, whereas Derlin-1, which has no effect on cross-presen-
tation (Figure 2B), could not be detected in OVA+ endosomes
(Figure S4B). Additionally, staining of isolated endosomes with
an antibody against the early endosome marker Rab5 demon-
strated a clear co-localization of Sec61 with Rab5 (Figure 4F),
confirming again that the vesicular Sec61-containing structures
indeed are endosomes enveloping high amounts of OVA.
Generation of an ER-Retained Intrabody That Prevents
Intracellular Recruitment of Sec61 toward Endosomes
To unequivocally demonstrate an involvement of Sec61 in anti-
gen translocation, we aimed for an approach to specifically
prevent the recruitment of Sec61 toward antigen-containing
endosomes. To this end, we used a phage display approach to
isolate a single chain variable fragment (scFv) antibody against
the first luminal loop of Sec61a (aa 55–76) and aimed to express
this antibody intracellularly with an ER targeting signal peptide
and a KDEL ER retention signal (ER intrabody). Because this
approach has been demonstrated before to prevent an intra-
body ligand from leaving the ER (Meli et al., 2014), we intended
to prevent Sec61 from being recruited from the ER toward
endosomes.
By screening the scFv library, we could isolate several putative
binding partners of Sec61 (Figure 5A), which after sequencing all
revealed to be the same clone (termed IB1) and showed a high
affinity for a peptide encompassing the first luminal loop of
Sec61a (Figure 5B). To investigate whether IB1 also recognized
cellular full-length Sec61a, we performed a pull-down experi-
ment with lysates from DCs using purified IB1. SDS-page anal-
ysis demonstrated the precipitation of a band with the expected
size of Sec61a (about 40 kDa) (Figure 5C), which was not present
using purified control IB (Figure S5A). Immunoblot analysis using
a Sec61-specific antibody revealed that this band indeed corre-
sponded to Sec61a (Figure 5D). Additionally, the expression of
his-tagged IB1 followed by Ni-NTA-based affinity chromato-
graphy and immunoblot analysis revealed a clear co-precipita-
tion of IB1 with Sec61 (Figure 5E), demonstrating that also
cellular IB1 can interact with Sec61.
Expression of the Sec61-specific intrabody in DCs followed by
immune fluorescence microscopy revealed that the intrabodyImmunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc. 853
(legend on next page)
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indeed was targeted toward the ER, where it co-localized with
calnexin and Sec61 (Figure 5F).
To analyze whether the intrabody indeed prevented the
recruitment of Sec61 toward antigen-containing endosomes,
we expressed it in DCs and monitored the presence of Sec61
in individual endosomes as described above. Expression of
the Sec61 intrabody clearly reduced the presence of Sec61 in
OVA-containing endosomes (Figure 5G), whereas the presence
of calnexin and TAP, two proteins that have been demonstrated
to be transported toward antigen-containing endosomes before
(Ackerman et al., 2003; Burgdorf et al., 2008; Saveanu et al.,
2009), remained unaltered (Figures 5H and 5I). In addition,
impaired Sec61 recruitment by IB1 was confirmed by confocal
laser microscopy (Figures 5J and 5K), demonstrating that
expression of the ER retained intrabody specifically keeps
Sec61 in the ER and prevents it from being recruited toward
endosomes.
To exclude that expression of the intrabody alters Sec61
functionality in the ER, we first monitored its total cellular
expression. Immunoblot analysis demonstrated that expression
of the intrabody in HEK293T cells or BM-DCs did not alter total
amounts of cellular Sec61 (Figure S5B). Next, we analyzed the
functionality of Sec61 in the ER. To this end, we made use of
the split Venus system (Grotzke et al., 2013), where one half
of the Venus protein (ZV2) is expressed in the cytosol and the
other part (ddV1Z) in the ER. Only if ddV1Z is translocated
into the cytosol by the ERAD machinery, fluorescence of the
Venus protein can occur. Expression of the Sec61-specific in-
trabody did not alter dislocation of Venus into the cytoplasm
by the ERAD machinery (Figure 5L), whereas both the addition
of ExoA (Figure S5C) and downregulation of Sec61 (Figure S5D)
impaired Venus translocation, confirming that full functionality
of Sec61 is required for Venus dislocation (Grotzke et al.,
2013) and that functionality of Sec61 in the ER after intrabody
expression remains intact.
To fully exclude any influence of the Sec61-specific intrabody
on ERAD functionality in the ER, we constructed fusion proteins
between the extended SIINFEKL epitope and TCRa or CD3d,
two well-known ERAD substrates (Yang et al., 1998; Yu et al.,
1997) whose degradation depends on ERAD-mediated disloca-Figure 3. Downregulation of Sec61a Prevents Antigen Export into the
(A) Expression of Sec61a1 and Sec61a2 in BM-DCs monitored by RT-PCR.
(B) Downregulation of Sec61a 24 hr after electroporation.
(C) BM-DCs were electroporated with siRNA. After 1 day, cells were incubated w
determined after 18 hr by ELISA.
(D) As in (C) using OT II cells.
(E) siRNA treated DCs were electroporated with OVA- or GFP-encoding mRNA.
(F) As in (C) using 10 nM SIINFEKL peptide.
(G) 18 hr after electroporation, siRNA-treated DCs were incubated with 5 mg/m
analyzed by flow cytometry.
(H) BM-DCs were electroporated with siRNA. After 24 hr, cells were incubated w
(I) siRNA-treated BM-DCs were incubated with OVA in the presence of the protea
amount of OVA determined by Western blot.
(J) siRNA-treated BM-DCs were incubated with 200 ng/ml OVA and 9mg/ml Cyt c
analyzed by flow cytometry.
(K) siRNA-treated BM-DCs were incubated with CCF4 for 1 hr, treated with 1 mg/
activity was determined by flow cytometry.
(L and M) As in (C and D) using beads coated with different ratios of OVA and BS
(N–P) Identical to (I–K) using bead-bound OVA, bead-bound Cyt c, and bead-b
independent experiments. Data are represented as mean ± SEM. MFI, mean fluotion from the ER. Importantly, MHC I-restricted presentation of
the SIINFEKL epitope from these fusion proteins remained unal-
tered by the expression of the Sec61-specific intrabody (Figures
5M and 5N), demonstrating again that IB1 doesn’t influence
overall ERAD activity in the ER.
Taken together, these data demonstrate that the Sec61-spe-
cific intrabody retains Sec61 in the ER and prevents it from being
recruited toward endosomes without influencing its functionality
in the ER.
Endosomal Sec61 Mediates Antigen Translocation from
Endosomes into the Cytosol
Next, we analyzed whether the exclusion of Sec61 from endoso-
mal compartments by ER retained intrabody expression altered
antigen translocation and cross-presentation. Therefore, we ex-
pressed the intrabody in both BM-DCs and the dendritic cell line
DC2.4 and analyzed cross-presentation. Intrabody expression
impaired cross-presentation in both cell types (Figures 6A and
S6A), whereas MHC II-restricted presentation (Figures 6B
and S6B), presentation of endogenous antigens (Figures 6C
and S6C) or T cell activation by peptide-loaded DCs (Figures
6D and S6D) remained unaltered, demonstrating a specific
effect of the intrabody on cross-presentation. These differences
were not due to altered antigen endocytosis, since intrabody
expression altered neither OVA uptake (Figure S6E) nor intracel-
lular routing toward Transferrin+EEA1+LAMP-1 endosomes
(Burgdorf et al., 2007) (Figure S6F).
To analyze whether impaired cross-presentation after Sec61
exclusion from antigen-containing endosomes was indeed
due to impaired antigen translocation into the cytosol, we again
used the approaches described above. We demonstrated that
expression of the Sec61-specific ER retained intrabody clearly
reduced the amount of OVA in the cytosolic fraction (Figure 6E)
and observed similar effects for soluble bovine serum albumin
(BSA) (Figure S6G) and henn egg lysozyme (HEL) (Figure S6H).
Additionally, the induction of apoptosis after addition of Cyt c
(Figure 6F) and the cleavage of cytosolic CCF4 after addition of
b-lactamase (Figure 6G) were also affected by the expression
of IB1, clearly demonstrating a role of endosomal Sec61 in anti-
gen translocation. Furthermore, we showed that expression ofCytoplasm and Cross-Presentation
ith OVA for 2 hr, fixed, and co-cultured with OT I T cells. T cell activation was
After another 3 hr, cells were fixed and co-cultured with OT I T cells.
l OVA. After another 6 hr, cells were stained with the 25.D1-16 antibody and
ith 250 ng/ml fluorochrome-labeled OVA and analyzed by flow cytometry.
some inhibitor MG132. After 45 min, cytosolic fractions were isolated and the
. After 8 hr, cells were harvested, stained with fluorochrome-labeled AnnV, and
ml b-lactamase for another 2 hr, and analyzed by flow cytometry. b-lactamase
A.
ound b-lactamase. All graphs depict representative results of at least three
rescence intensity. See also Figure S3.
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Figure 4. Sec61 Expression in Antigen-Containing Endosomes
(A) Transmission electron microscopy image of BM-DCs transfected with GFP-Sec61b and incubated with OVA. Sections were immuno labeled with a GFP-
specific antibody and protein A-coated 15 nm gold beads. Scale bar represents 150 nm. ER, endoplasmic reticulum; M, mitochondrium; N, nucleus; E,
endosome, PM, plasma membrane.
(B and C) Correlative light and electron microscopy (CLEM) of BM-DCs transfected with GFP-Sec61b and incubated with fluorochrome-labeled OVA. Immuno-
labeling of Sec61 was performed as in (A). OVA is depicted in red, GFP-Sec61b in green, and the nucleus stained with DAPI in blue. Arrows indicate gold label
associated with endosomes. Scale bar represents 150 nm. CLSM, confocal laser scanning microscopy; TEM, transmission electron microscopy.
(D) Quantitative analysis of Sec61 in OVA-positive endosomes. Beads in all OVA+ endosomes from 14 GFP-Sec61-negative (78 endosomes) or 25 GFP-Sec61-
positive (115 endosomes) cells from the same sample were counted.
(E) BM-DCswere transducedwith lentivirus expressing GFP or GFP-Sec61b. After incubation with fluorochrome-labeled OVA, endosome fractions were isolated
and analyzed by flow cytometry. Right histograms depict OVA+ endosomes after gating as indicated.
(F) DC2.4 cells were transduced with lentivirus expressing GFP or GFP-Sec61b. After incubation with fluorochrome-labeled OVA, endosome fractions were
isolated and stained with a Rab5-specific antibody. All graphs depict representative results of at least three independent experiments. Data are represented as
mean ± SEM. MFI, mean fluorescence intensity. See also Figure S4.IB1 also impaired the recruitment of Sec61 to phagosomes (Fig-
ure S6I) and that IB1 expression reduced cross-presentation
of particulate OVA in BM-DCs (Figure 6H) and DC2.4 cells
(Figure S6J), without affecting MHC II-restricted presentation
(Figures 6I and S6K) and overall phagocytosis (Figure S6L).
Furthermore, the translocation of bead-bound OVA (Figure 6J),
bead-bound Cyt c (Figure 6K), and bead-bound b-lactamase
(Figure 6L) was also impaired, demonstrating that endosomal
Sec61 is not only important for translocation of soluble but
also of particulate antigens.
To finally demonstrate that intrabody-mediated retention of
Sec61 caused the observed reduction in antigen translocation
and cross-presentation, we generated an intrabody variant that
lacks the KDEL ER retention signal (IB1DKDEL). This mutant856 Immunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc.was targeted to the ER, where it co-localized with calnexin (Fig-
ure 6M) and Sec61 (Figure 6N), but because of the lack of KDEL
retention signal, was also detected in the Golgi (Figure 6O). As
expected, the expression of IB1DKDEL did not influence the
recruitment of Sec61 toward antigen-containing endosomes
(Figure 6P), confirming that the KDEL signal indeedwas essential
to prevent such transport. Accordingly, although IB1DKDEL co-
localized with Sec61 in the ER (Figure 6N), its expression didn’t
affect cross-presentation in BM-DCs (Figure 6Q) or in the
DC2.4 cell line (Figure S6M). Similarly, expression of IB1DKDEL
did not alter the translocation of OVA (Figure 6R), Cyt c
(Figure 6S), or b-lactamase (Figure 6T) into the cytosol, demon-
strating that reduced cross-presentation after intrabody expres-
sion indeed was due to the impaired recruitment of Sec61
toward antigen-containing endosomes and not by unspecific ef-
fects caused by the presence of a Sec61-specific intrabody in
the ER.
Taken together, these data strongly demonstrate that endoso-
mal Sec61 mediates antigen translocation into the cytosol for
cross-presentation.
Recruitment of Sec61 and Hence Antigen Translocation
and Cross-Presentation Depend on Signaling via TRIF
The recruitment of Sec61 toward endosomes has been associ-
ated with the presence of microbial substances (Goldszmid
et al., 2009). If Sec61 indeed mediates antigen translocation
into the cytosol as described above, this would imply that anti-
gen translocation and hence cross-presentation should depend
on the presence of TLR ligands. In a previous study, we demon-
strated that peptide loading onto MHC I molecules for efficient
cross-presentation in fact depends on intact TRIF signaling
(Burgdorf et al., 2008), but we were unable to identify the
underlying molecular mechanisms. Here, we proceeded to
investigate whether impaired cross-presentation in the absence
of TRIF-signaling indeed might be due to an altered recruitment
of Sec61 toward antigen-containing endosomes and hence to
changes in antigen translocation.
To test this hypothesis, we first incubated wild-type or TRIF-
deficient (Ticam1/) DCs with OVA and analyzed cross-presen-
tation. In accordance to previous observations (Burgdorf et al.,
2008), cross-presentation was reduced in TRIF-deficient DCs
(Figure 7A), whereas MHC II-restricted presentation (Figure 7B),
endogenous presentation (Figure 7C) and T cell activation after
external peptide loading (Figure 7D) were not affected. Consis-
tently, cross-presentation was also reduced in wild-type DCs
using purified endotoxin-free (endograde) OVA (Figure S7A),
confirming a stimulatory role of endotoxins on cross-presenta-
tion. Differences in cross-presentation were not due to altered
antigen internalization, as OVA uptake (Figure S7B) and subcel-
lular localization in Transferrin+EEA1+LAMP-1 endosomes
(Figure S7C) remained unaltered. Staining with the 25.D1-16
antibody revealed that peptide loading on MHC I molecules
was impaired in TRIF-deficient DCs, confirming previous
observations (Figure S7D). Next, we analyzed whether reduced
cross-presentation was due to an impaired antigen export into
the cytosol. We could demonstrate that in TRIF-deficient DCs,
the transport of OVA into the cytosol (Figure 7E), the induction
of apoptosis after addition of Cyt c (Figure 7F), and the cleavage
of the cytosolic CCF4 after addition of b-lactamase (Figure 7G)
were reduced, all demonstrating that antigen translocation into
the cytosol indeed was prevented. To investigate whether
impaired antigen translocation was due to an altered recruitment
of Sec61 toward antigen-containing endosomes, we again
analyzed Sec61 on individual endosomes as described above.
Importantly, only a marginal recruitment of Sec61 toward
OVA+ endosomes was detected in TRIF-deficient DCs (Fig-
ure 7H), showing that TRIF signaling was indeed necessary for
efficient recruitment of Sec61. Consistently, such recruitment
was also impaired using endotoxin-free OVA (Figure S7E) or
transferrin from human blood (Figure S7F), confirming an impor-
tant role for TRIF signaling. Accordingly, in contrast to OVA-
treated DCs (Figure 4F), Sec61 could be detected only in a mi-
nority of Rab5+ endosomes in the absence of OVA (Figure S7G).Taken together, we demonstrated that endosomal Sec61 me-
diates antigen translocation into the cytosol and that recruitment
of Sec61 from the ER toward antigen-containing endosomes is
mediated by TRIF signaling.
DISCUSSION
In this study, we have provided functional evidence that the
ERAD member Sec61 mediates antigen transport from endo-
somes into the cytosol.
A putative role of the ERADmachinery in antigen translocation
has been postulated based on observations that ExoA, which
binds to Sec61, reduces cross-presentation (Ackerman et al.,
2006). But because no direct role of Sec61 could be demon-
strated, its involvement in cross-presentation was questioned
and discussed controversially (Joffre et al., 2012; Kurts and
Wagner, 2011; Nair-Gupta and Blander, 2013). Here, we provide
functional evidence that Sec61 indeed plays an essential role in
antigen translocation and demonstrated that Sec61 is present in
antigen-containing endosomes after stimulation with microbial
substances. Retention of Sec61 in the ER by the expression of
a Sec61-specific ER intrabody prevented its recruitment toward
endosomes without affecting its activity in the ER, strongly
demonstrating that endosomal Sec61 is essential for efficient
antigen translocation into the cytosol and hence for cross-pre-
sentation. Nevertheless, it is not unreasonable to think that
Sec61might not be the only translocon enabling antigen translo-
cation into the cytosol, a notion that might be further supported
by observations demonstrating that dislocation at the ER can
also be mediated by Hrd1, independent of Sec61 (Stein et al.,
2014). In this study, we demonstrated that downregulation of
Hrd1 indeed reduced cross-presentation. However, because
silencing of Hrd1 also affected MHC II-restricted presentation,
these results should be interpreted with care and future experi-
ments will have to show whether reduced cross-presentation
indeed was due to altered antigen translocation into the cytosol
or eventually to a more general cellular stress induced by
silencing of Hrd1. Therefore, the precise role of Hrd1 in cross-
presentation still needs to be elucidated.
In this study, we demonstrated that Sec61 activity is required
for translocation ofOVA,HEL, BSA,Cyt c, and b-lactamase. After
isolation of the cytosolic fraction, we observed mainly full-length
OVA, which was rapidly degraded in the absence of a protea-
some inhibitor. Oneexplanation for the absence of clearly detect-
ableOVAdegradationproductsmight be its internalization via the
mannose receptor, which targets its ligands toward early endo-
somes (Burgdorf et al., 2007), where they are rescued from lyso-
somal degradation and remain stable for at least 24 hr (Chatterjee
et al., 2012). Indeed, also in total cell lysates, we observed
mainly full-lengthOVA. Additionally, translocation of b-lactamase
(Cebrian et al., 2011), Cyt c (Lin et al., 2008), and horseradish
peroxidase (Giodini and Cresswell, 2008) was associated with
the retention of their activity, also implying the translocation of
full-length proteins. However, we cannot exclude the presence
of minor amounts of degradation products. Alternatively, degra-
dation products could also have been rapidly de-biotinylated and
therefore escaped detection in our experimental setup.
Silencing at the protein level using intrabodies has been used
occasionally for functional analysis (Meli et al., 2014; MarschallImmunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc. 857
Figure 5. Isolation and Purification of a Sec61-Specific Intrabody
(A) Isolation of different antibody clones against Sec61a55–76 by phage display.
(B) Binding of purified IB1 to Sec61a55–76 or control peptides depicted by ELISA.
(C) Immune precipitation from cell lysates of BM-DCs using purified IB1. Samples were loaded on an SDS-page and stained with Coomassie blue.
(legend continued on next page)
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et al., 2014). Here, by the use of a Sec61-specific ER retained
intrabody, isolated by phage display, we could demonstrate
that endosomal Sec61 was indeed required for efficient antigen
translocation and cross-presentation. This implies that Sec61
needs to be transported from the ER toward antigen-containing
endosomes, which occurred in a TRIF-dependent fashion after
stimulation with endotoxins, resulting in a clear dependency
of efficient cross-presentation on TRIF-signaling. However,
cross-presentation was not completely abolished in Ticam1/
DCs, and marginal recruitment of Sec61 toward endosomes
was also observed in Ticam1/ DCs, in DCs treated with endo-
toxin-free OVA or human transferrin or in untreated cells, point-
ing out that residual cross-presentation can take place also in
Ticam1/ DCs, albeit with clearly reduced efficiency. Future ex-
periments will have to show whether also other signaling path-
ways contribute to the recruitment of Sec61 toward endosomes.
Previous studies reported already of the transport of ER pro-
teins toward endosomal membranes upon stimulation with living
protozoa, LPS, or yeast cells (Burgdorf et al., 2008; Saveanu
et al., 2009). Notably, the ER-resident aminopeptidase ERAP,
which is responsible for peptide trimming in theER,wasexcluded
from antigen-containing endosomes upon stimulation with yeast
cells (Saveanu et al., 2009). Similarly, in this study, we could
not detect any presence of Derlin-1 within OVA-containing
endosomes, pointing out that only distinct ER proteins undergo
a directed ER-to-endosome transport. However, the exact
mechanisms of this transport remain largely unclear. It has
beenpostulated that transport of ERproteins toward endosomes
might occur via the ER-Golgi intermediate compartment (ERGIC)
in a Sec22b-dependent fashion, because downregulation of
Sec22b impairs antigen translocation into the cytosol and
cross-presentation (Cebrian et al., 2011). Recent high-resolution
microscopy studies revealed the presence of contact sides be-
tween endosomes and the ER and demonstrated that endo-
somes mature and traffic closely coupled to the ER membrane
rather than in isolation (Friedman et al., 2013), pointing out that
a direct contact between endosomes and the ER membrane
might also lead to the transfer of ER proteins toward endosomes.
Taken together, we demonstrated that antigen translocation
into the cytosol is mediated by Sec61, which is recruited
toward antigen-containing endosomes upon stimulation with(D) Immune precipitation from cell lysates of BM-DCs using purified IB1 or contr
(E) HEK293T cells were transfected with 6His-tagged IB1. Cell lysates were subj
(F) Immune fluorescence microscopy images of BM-DCs transfected with IB1 o
trabodies. Nuclei (blue) were stained with DAPI. Co-localization was analyzed by
(MOC). Scale bars represent 10 mm.
(G) DC2.4 cells were transduced with lentivirus expressing IB1 or control intrabo
labeled OVA before the endosome fraction was isolated and analyzed by flow cy
(H) DC2.4 cells were transduced with lentivirus expressing GFP or a GFP-Sec6
calnexin.
(I) As in (H) using TAP-specific antibodies.
(J) Confocal laser scanning microscopy on OVA-treated JAWSII cells expressing
Sec61 in green, and intrabody in blue. Scale bars represent 10 mm in large pane
(K) Quantification of co-localization between OVA and GFP-Sec61 in 15 random
(L) HEK293T cells stably expressing a split Venus protein (293T.FluERAD) were tra
of the proteasome inhibitor MG132. Fluorescence of the Venus protein was dete
(M) BM-DCs were transduced with lentivirus expressing IB1 or control IB and t
SIINFEKL epitope. MHC I-restricted presentation was determined after co-cultu
(N) Identical to (M) for a fusion protein between CD3d and SIINFEKL. All graphs de
represented as mean ± SEM. SA, streptavidin, MFI, mean fluorescence intensityTLR ligands. These findings improve our understanding of the
cell-biological mechanisms of antigen cross-presentation and
the initiation of adaptive immune responses under inflammatory
conditions.
EXPERIMENTAL PROCEDURES
For detailed protocols, see Supplemental Experimental Procedures.
Mice
For all experiments, mice between 8 and 16 weeks of age bred in specific
pathogen-free conditions were used in accordance with local animal experi-
mentation guidelines.
Antibodies and Reagents
Mouse 25.D1-16 antibody was from BD Biosciences, rabbit anti-actin (20-33)
and mouse anti-derlin-1 (derlin-1-1) from Sigma, rabbit anti Sec61a (07-204)
from Upstat, rabbit anti-Sec61b (ab78276), rabbit anti-GFP (ab290), and
mouse anti-hexahistidine (ab18184) from Abcam, rabbit anti-Sec61g (11147-
2-AP) from Proteintech, rat anti-LAMP-1 (1D4B) from BD Biosciences, rabbit
anti-EEA1 (H-300) and rabbit anti-TAP (M18) from Santa Cruz, and rabbit
anti-calnexin (ab22595) from Abcam. AnnexinV was obtained from BD
Biosciences, CCF4 from Life Technologies, and b-lactamase (Enterococcus
cloacae) and horse Cyt c from Sigma. Endotoxin-free (Endograde) OVA was
purchased from Hyglos.
Generation of BM-DCs
BM-DCs were generated using a GM-CSF-producing cell line as described
previously (Burgdorf et al., 2007)
Analysis of Antigen Presentation
BM-DCs were incubated with the indicated amounts of OVA or SIINFEKL
peptide. After 2 hr, cells were washed and OT I or OT II T cells were added.
If required, DCswere fixedwith 0.008%glutaraldehyhe for 60 s before addition
of T cells. For detection of endogenous antigen presentation, OVA-encoding
mRNA was generated using the mMessage mMachine T3 Transcription kit
(Life Technologies) and electroporated into the DCs using a square wave pulse
of 300V during 6 msec. Concentrations of interleukin-2 (IL-2) were determined
by ELISA after 18 hr. For staining experiments with the 25.D1-16 antibody,
cells were incubated with 5 mg/ml OVA for the indicated time points.
Analysis of Antigen Translocation into the Cytosol
The presence of OVA in the cytosolic fraction of OVA-treated DCs was
performed as demonstrated before (Zehner et al., 2011). Briefly, cells were
incubated with 0.5 mg/ml biotinylated OVA in the presence of 5 mM of the
proteasome inhibitor MG132. After 45 min, the cytosolic fraction was isolatedol IB.
ected to Ni-NTA-affinity chromatography and analyzed by Western blot.
r control IB. Cells were stained using antibodies for Sec61b, Calnexin, and in-
the Pearson correlation coefficient (PCC) and the Mander’s overlap coefficient
dy and with GFP or with GFP-Sec61b. Cells were treated with fluorochrome-
tometry.
1b and treated with OVA. Endosomes were stained with antibodies against
GFP-Sec61b and control IB or IB1. In merged images, OVA is depicted in red,
l and 1 mm in enlarged views.
cells expressing control IB or IB1.
nsfected with IB1 or control intrabody. After 48 hr, cells were treated with 5 mM
rmined by flow cytometry.
ransfected with mRNA encoding a fusion protein between the TCRa and the
re with OT I T cells by ELISA.
pict representative results of at least three independent experiments. Data are
. See also Figure S5.
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Figure 6. Exclusion of Sec61 from Antigen-Containing Endosomes Prevents Antigen Translocation into the Cytosol and Cross-Presentation
(A) BM-DCswere transduced with lentivirus expressing IB1 or control IB, incubated with OVA for 2 hr, fixed, and co-cultured with OT I T cells. T cell activation was
determined by ELISA.
(legend continued on next page)
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Figure 7. Impaired Recruitment of Sec61,
Antigen Translocation and Cross-Presenta-
tion in TRIF-Deficient DCs
(A) Wild-type or TRIF-deficient BM-DCs were
incubated with OVA for 2 hr, fixed, and co-cultured
with OT I T cells. T cell activation was depicted by
ELISA.
(B) As in (A) using OT II cells.
(C) Wild-type or TRIF-deficient BM-DCs were
transfected with GFP- or OVA encoding mRNA.
After 3 hr, cells were fixed and co-cultured with
OT I T cells.
(D) As in (A) using 10 nM SIINFEKL peptide.
(E) Wild-type or TRIF-deficient DCs were incu-
bated with OVA for 45 min. Subsequently, the
cytosolic fraction of these cells was isolated and
OVA was detected by Western blot.
(F) Wild-type or TRIF-deficient BM-DCs were
incubated with 200 ng/ml OVA and 9 mg/ml Cyt c.
After 8 hr, cells were harvested, stained with AnnV,
and analyzed by flow cytometry.
(G) Wild-type or TRIF-deficient BM-DCs were
loaded with CCF4 for 1 hr and incubated with
1 mg/ml b-lactamase. After another 2 hr, b-lacta-
mase activity was determined by flow cytometry.
(H) Wild-type or TRIF-deficient BM-DCs were
transduced with lentivirus expressing GFP or
GFP-Sec61b. Cells were treated with 500 ng/ml
fluorochrome-labeled OVA. Subsequently, endo-
somes were isolated and analyzed by flow cy-
tometry. All graphs depict representative results of
at least three independent experiments. Data are
represented as mean ± SEM. MFI, mean fluores-
cence intensity. See also Figure S7.using the subcellular proteome extraction kit (Calbiochem). Cytosolic OVAwas
concentrated by affinity chromatography using neutravidin-coated beads and
analyzed by Western blot.
For translocation of Cyt c, DCs were incubated with 200 ng/ml OVA and
9 mg/ml Cyt c in the presence of 10 mM NH4Cl. After 8 hr or 18 hr, cells(B) As in (A) using OT II cells.
(C) BM-DCs were transduced with lentivirus expressing IB1 or control IB and elec
co-cultured with OT I T cells.
(D) As in (A) using 10 nM SIINFEKL peptide.
(E) BM-DCswere transducedwith lentivirus expressing IB1 or control IB and incub
cytosolic fractions were isolated and the amount of OVA determined by Western
(F) BM-DCs transducedwith lentivirus expressing IB1 or control IB were incubated
with fluorochrome-labeled AnnV, and analyzed by flow cytometry.
(G) BM-DCs transduced with lentivirus expressing IB1 or control IB were incuba
b-lactamase activity was determined by flow cytometry.
(H) BM-DCs were transduced with lentivirus expressing IB1 or control IB. Cells w
3 hr, fixed and co-cultured with OT I T cells.
(I) As in (H) using OT II cells.
(J–L) As in (E–G) using bead-bound OVA, bead-bound Cyt c, or bead-bound b-la
(M–O) Immune fluorescencemicroscopy images of BM-DCs transfectedwith IB1D
(N), and the Golgi marker GM130 (O). Nuclei (blue) were stained with DAPI. Scal
(P) DC2.4 cells were transduced with lentivirus expressing IB1DKDEL or control in
labeled OVA before the endosome fraction was isolated and analyzed by flow cy
(Q) BM-DCs were transduced with lentivirus expressing IB1DKDEL or control IB.
(R–T) As in (E–G) expressing IB1DKDEL instead of IB1. All graphs depict represent
mean ± SEM. MFI, mean fluorescence intensity. See also Figure S6.were harvested, stained with fluorochrome-labeled AnnexinV, and analyzed
by flow cytometry.
Translocation of b-lactamase was performed as described before (Cebrian
et al., 2011). Briefly, cells were pre-treated with CCF4 staining solution (Life
Technologies). After 1 hr, cells were incubated with 1 mg/ml b-lactamase fortroporated with GFP- or OVA-encoding mRNA. After 3 hr, cells were fixed and
atedwith OVA in the presence of the proteasome inhibitorMG132. After 45min,
blot.
with 200 ng/ml OVA and 9mg/ml Cyt c. After 8 hr, cells were harvested, stained
ted with CCF4 for 1 hr and treated with 1 mg/ml b-lactamase for another 2 hr.
ere incubated with latex beads coated with different ratios of OVA and BSA for
ctamase.
KDEL. Cells were stained using antibodies for intrabodies, Calnexin (M), Sec61
e bars represent 10 mm.
trabody and with GFP or a GFP-Sec61b. Cells were treated with fluorochrome-
tometry.
Cells were incubated with OVA for 2 hr, fixed, and co-cultured with OT I T cells.
ative results of at least three independent experiments. Data are represented as
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another 2 hr. Afterward, cells were analyzed by flow cytometry. Translocation
of b-lactamase was quantified by the ratio between fluorescence at 450 nm
(cleaved CCF4) and at 535 nm (uncleaved CCF4).
Monitoring Total OVA Uptake
BM-DCswere incubated with 250 ng/ml fluorochrome-labeled OVA for 15min.
OVA uptake was monitored by flow cytometry.
RT-PCR of sec61a Subunits
cDNA from BM-DCs was generated using the Superscript II reverse transcrip-
tase (Life Technologies). Expression of different subunits was determined
by PCR using CCGATGGACCTTCCAATC and CACTGAGCCGAACGATTCC
(a1), TCGTGTTGACTTGCCCATT and AAATATGGCTCCCATAGACTCAG (a
2), or CAGCAATGCATCCTGCAC and GGATGACCTTGCCCACAG (GAPDH)
as primers.
Immunofluorescence Microscopy
BM-DCs were incubated with 250 ng/ml fluorochrome-labeled OVA or with
1 mg/ml fluorochrome-labeled transferrin for 15 min and chased with me-
dium for another 15 min. Staining experiments were performed as
described previously (Zehner et al., 2011). Nuclei were visualized with
1 mg/mL 4’,6-diamidino-2-phenylindole (DAPI). Cells were analyzed with
an ApoTome microscope (Zeiss). Co-localization was quantified using
ImageJ software.
To analyze the effect of intrabody expression onSec61 recruitment, we grew
JAWSII cells expressing GFP-Sec61b and 6His-tagged control IB or IB1 on
poly-L-lysine-coated coverslips and treated them with fluorochrome-conju-
gated OVA. After rinsing twice with PBS, cells were fixed at RT with 4% PFA
in PBS for 15 min. Cells were quenched at RT with 50 mM NH4Cl in PBS
for 20 min, washed three times for 5 min in PBS, permeabilised at RT for
3–5 min using 0.1% Triton X-100 in PBS, washed three times for 5 min with
PBS, and blocked at RT for 1 hr using 3% BSA in PBS. Cells were stained
with anti-hexahistidine and anti-GFP in 1% BSA-PBS at 4C overnight. After-
ward washing, cells were stained with secondary antibodies in 1% BSA-PBS
at RT for 2 hr. Coverslips were washed four times with PBS, mounted on
microscopy slides using ProLong Gold (P36930, Invitrogen,) and cured
overnight.
Samples were stored at 4C until imaging on a TCS-SP8 confocal laser
scanning microscope (Leica) at the Light Microscopy Facility (LMF) at the
German Centre for Neurodegenerative Diseases (DZNE) in Bonn. Images of
the deep red channel (ovalbumin), red channel (intrabody), and green channel
(Sec61-GFP) were recorded sequentially at 600 Hz and shown at arbitrary
scaling. For quantification, deep red channel images were processed using
the ImageJ software applying a Gaussian blur to segment subcellular
ovalbumin-rich areas via thresholding. For further analysis, raw images were
smoothed applying a normalized 33 3 pixel kernel. As a measure of co-local-
ization, the Pearson correlation coefficient between the Sec61-GFP signal and
the raw ovalbumin signal within the segmented OVA-rich area of each cellular
slice was calculated.
Analysis of Sec61 Recruitment to Antigen-Containing Endosomes
by Flow Cytometry
BM-DCs were transduced with lentivirus expressing GFP or a GFP fusion pro-
tein with Sec61b. 4 days after transduction, cells were treated with 500 ng/ml
fluorochrome-labeled OVA for 20 min and chased with medium for another
20 min. Afterward, the endosomal fraction was isolated and analyzed by
flow cytometry as described before (Zehner et al., 2012).
For antibody staining, endosomes were fixed and incubated with the
respective antibodies as described before (Zehner et al., 2012).
Generation of TCRa or CD3d Fusion Proteins with SIINFEKL
The extended SIINFEKL epitope from OVA (LEQLESIINFEKLTEWTS) was
cloned to the C terminus of TCRa or CD3d.
Statistical Analysis
p values were calculated by two-tailed t test (nR 3) using Excel (Microsoft) or
Prism (Graphpad) Software. Quantification of Western blots was performed
using ImageJ.862 Immunity 42, 850–863, May 19, 2015 ª2015 Elsevier Inc.SUPPLEMENTAL INFORMATION
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